Physicochemical characterization and membrane binding properties of camptothecin

Journal of Pharmaceutical Sciences

Volumn 97, Issue 10, 2008, Pages 4379-4390

  Selvi, Bilge ^a   Patel, Sanjay ^a   Savva, Michalakis ^a  

^a LONG ISLAND UNIVERSITY   (United States)

Author keywords

Anisotropy; Camptothecin; Fluorescence spectroscopy; Hydrolysis; pH dependent partition coefficient

Indexed keywords

AMPHOLYTE; CAMPTOTHECIN; NITROGEN;

ACIDITY; ANISOTROPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILAYER MEMBRANE; DRUG SOLUBILITY; FLUORESCENCE SPECTROSCOPY; MEMBRANE BINDING; PARTITION COEFFICIENT; PHYSICAL CHEMISTRY; PROTON TRANSPORT; TEMPERATURE SENSITIVITY;

EID: 55749084716     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21314     Document Type: Article

References (39)

1. Wall ME, Wani MC. 1991. Chemistry and antitumor activities of camptothecins. In: Potmesil M, Kohn KW, editors. DNA topoisomerases in cancer. New York: Oxford University Press. pp 93-102.
2. Muggia FM. 1995. Twenty years later: Review of clinical trials with camptothecin sodium (NSC-100880). In: Potmesil M, Pinedo H, editors. Camptothecins: New anticancer agents. Boca Raton: CRC Press. p 44.
3. O'Leary J, Muggian FM. 1998. Camptothecins: A review of their development and schedules of administration. Eur J Cancer 34:1500-1508.
4. Gottlieb JA, Guarino AM, Call JB, Block JB. 1970. Preliminary pharmacological and clinical evaluation of camptothecin sodium (NCS 100880). Cancer Chemother Rep 54:461-470.
5. Wani MC, Ronman PE, Lindley JT, Wall ME. 1980. Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogs. J Med Chem 23:554-560.
6. Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y. 1989. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 49:1465-1469.
7. Tyner MK, Schiffman SR, Giannelis PE. 2003. Nanobiohybrids as delivery vehicle for camptothecin. J Control Release 95:501-514.
8. Cortesi R, Esposito E, Maietti A, Menegatti E, Nastruzzi C. 1997. Formulation study for the antitumor drug camptothecin: Liposomes, micellar solutions and a microemulsion. Int J Pharm 159:95-103.
9. Koo MO, Rubinstein I, Onyuksel HJ. 2006. Camptothecin in sterically stabilized phospholipid micelles: A novel nanomedicine. Nanosci Nanotechnol 6:2996-3000.
10. Burke TG, Gao X. 1994. Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine. J Pharm Sci 7:967-969.
11. Bom D, Curran DP, Zhang J, Zimmer SG, Bevins R, Kruszewski S, Howe JN, Bingcang A, Latus LJ, Burke TG. 2001. The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity. J Control Release 74:325-333.
12. Hatefi A, Amsden B. 2002. Camptothecin delivery methods. Pharm Res 19:1389-1399.
13. Glabermen U, Rabinowitz I, Verschraegen CF. 2005. Alternative administration of camptothecin analogues. Expert Opin Drug Deliv 2:323-333.
14. Slichenmyer WJ, Rowingsky EK, Donehower RC, Kaufmann SH. 1993. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85:271-291.
15. Warner DL, Burke TG. 1997. Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs. J Chromatogr B Biomed Sci Appl 691:161-171.
16. Nabiev I, Fleury F, Kudelina I, Pommier Y, Charton F, Riou JF, Alix AJP, Manfait M. 1998. Spectroscopic and biochemical characterisation of self-aggregates formed by antitumor drugs of the camptothecin family: Their possible role in the unique mode of drug action. Biochem Pharmacol 55:1163-1174.
17. Kim JH, Lee SK, Lim JL, Shin HJ, Hong C. 2002. Preformulation studies of a novel camptothecin anticancer agent, CKD-602: Physicochemical characterization and hydrolytic equilibrium kinetics. Int J Pharm 239:207-211.
18. Peikov V, Ugwu S, Parmar M, Zhang A, Ahmad I. 2005. pH-dependent association of SN-38 with lipid bilayers of a novel liposomal formulation. Int J Pharm 299:92-99.
19. Shinitzky M, Dianoux AC, Gitler C, Weber G. 1971. Microviscosity and order in the hydrocarbon region of micelles and membranes determined with fluorescent probe. I. Synthetic micelles. Biochemistry 10:2106-2113.
20. Lentz BR, Moore BM, Barrow DA. 1979. Light-scattering effects in the measurement of membrane microviscosity with diphenylhexatriene. Biophys J 25:489-494.
21. Burke TG, Tritton TR. 1985. Structural basis of anthracycline selectivity for unilamellar phosphatidylcholine vesicles: An equilibrium binding stud. Biochemistry 24:1768-1776.
22. Burke TG, Staubus AE, Mishra AK. 1992. Liposomal stabilization of camptothecin's lactone ring. J Am Chem Soc 114:8318-8319.
23. Mi Z, Burke GT. 1994. Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry 33:10325-10336.
24. Burke TG, Mishra KA, Wani MC, Wall ME. 1993. Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry 32:5352-5364.
25. Chourpa I, Millot JM, Sockalingum GD, Riou JF, Manfait M. 1998. Kinetics of lactone hydrolysis in antitumor drugs of camptothecin series as studied by fluorescence spectroscopy. Biochim Biophys Acta 1379:353-366.
26. Saetern AM, Flaten GE, Brand M. 2004. A method to determine the incorporation capacity of camptothecin liposomes. AAPS Pharm Sci Tech 5:40.
27. Strel'tsov SA, Grokhovskii SL, Kudelina IA, Oleinikov VA, Zhuze AL. 2001. Interaction of topotecan, DNA topoisomerase I inhibitor, with double-stranded polydeoxyribonucleotides 1. Topotecan dimerization in solution. Mol Biol 35:432-441.
28. Fassberg J, Stella JV. 1992. A kinetic and mechanictic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 81:676-684.
29. Sanna N, Chillemi G, Grandi A, Castelli S, Desideri A, Barone VJ. 2005. New hints on the pH-driven tautomeric equilibria of the topotecan anticancer drug in aqueous solutions from an integrated spectroscopic and quantum-mechanical approach. Am Chem Soc 127:15429-15436.
30. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3-25.
31. Yalkowsky SH, Valvani SC. 1981. Correlation of water solubility with octanol-water partition coefficient: A response. J Pharm Sci 70:1177-1178.
32. Yalkowsky SH. 1999. Solubility and solubilization in aqueous media, New York, New York.
33. Yalkowsky SH, Valvani SC, Roseman TJ. 1983. Solubility and partitioning VI: Octanol solubility and octanol-water partition coefficients. J Pharm Sci 72:866-870.
34. Solntsev KM, Sullivan EN, Tolbert LM, Ashkenazi S, Leidderman P, Huppert D. 2004. Excited-state proton transfer reactions of 10-hydroxycamptothecin. J Am Chem Soc 126:12701-12708.
35. Kingsbury W, Boehm J, Jakas D, Holden K, Hecht S, Gallgher G, Caranfa M, McCabe F, Faucette L, Johnson R, Hertzberg R. 1991. Synthesis of water soluble (aminoaklyl) camptothecin analogues: Inhibition of topoisomerase I and antitumor activity. J Med Chem 34:98-107.
36. Warnecke A, Kratz F. 2003. Derivatives of camptothecin as albumin-binding prodrugs: Synthesis and antitumor efficacy. Bioconjugate Chem 14:377-387.
37. Enoch GH, Strittmatter P. 1979. Formation and properties of 1000-A-diameter, single-bilayer phospholipid vesicles. Proc Natl Acad Sci USA 76:145-149.
38. Opanasopit P, Ngawhirunpat T, Chaidedgumjorn A, Rojanarata T, Apirakaramwong A, Phongying S, Choochottiros C, Chirachanchai S. 2006. Incorporation of camptothecin into N-phthaloyl chitosan-g-mPEG self-assembly micellar system. Eur J Pharm Biopharm 64:269-276.
39. Opanasopit P, Yokoyama M, Watanabe M, Kawano K, Maitani Y, Okano T. 2005. Influence of serum and albumins from different species on stability of camptothecin loaded micelles. J Control Release 104:313-321.